HOB Biotech Group Corp Ltd Asset Resilience Ratio
HOB Biotech Group Corp Ltd asset resilience ratio. HOB Biotech Group Corp Ltd (688656) has an Asset Resilience Ratio of 2.62% as of September 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See HOB Biotech Group Corp Ltd liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of HOB Biotech Group Corp Ltd (2021–2022)
Asset resilience ratio of HOB Biotech Group Corp Ltd from 2021 to 2022. This chart shows how HOB Biotech Group Corp Ltd's Asset Resilience Ratio has changed over time. Read 688656 total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down HOB Biotech Group Corp Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is HOB Biotech Group Corp Ltd's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥25.01 Million | 2.62% |
| Total Liquid Assets | CN¥25.01 Million | 2.62% |
Asset Resilience Insights
- Limited Liquidity: HOB Biotech Group Corp Ltd maintains only 2.62% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
HOB Biotech Group Corp Ltd Industry Peers by Asset Resilience Ratio
Compare HOB Biotech Group Corp Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Demant A/S
CO:DEMANT |
Medical Devices | -2.59% |
|
Shanghai Sanyou Medical Co Ltd
SHG:688085 |
Medical Devices | 7.69% |
|
CareRay Digital Medical Technology Co Ltd
SHG:688607 |
Medical Devices | 16.21% |
|
Cleo Diagnostics Ltd
AU:COV |
Medical Devices | 94.64% |
|
Memphasys Ltd
AU:MEM |
Medical Devices | 0.00% |
|
Cochlear Ltd
AU:COH |
Medical Devices | 9.76% |
|
Anteris Technologies Global Corp
AU:AVR |
Medical Devices | 33.27% |
|
Polynovo Ltd
AU:PNV |
Medical Devices | 0.04% |
HOB Biotech Group Corp Ltd Asset Resilience Ratio by Year (2021–2022)
HOB Biotech Group Corp Ltd asset resilience ratio by year from 2021 to 2022. The table below shows the annual Asset Resilience Ratio data for HOB Biotech Group Corp Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 14.32% | CN¥135.23 Million ≈ $19.79 Million |
CN¥944.56 Million ≈ $138.22 Million |
+13.74pp |
| 2021-12-31 | 0.58% | CN¥5.01 Million ≈ $733.28K |
CN¥863.92 Million ≈ $126.42 Million |
-- |
About HOB Biotech Group Corp Ltd
HOB Biotech Group Corp.,Ltd. operates as an in vitro diagnostic company in China and internationally. It provides diagnostic tools, such as line immune, enzyme-linked immunosorbent, and chemiluminescent paramagnetic microparticle immune assays to laboratories and hospitals for the improvement of allergy and autoimmune disease patient care. HOB Biotech Group Corp.,Ltd was founded in 2009 and is ba… Read more